ABBV-744 CANCER TREATMENT CLINICAL TRIALS - AN OVERVIEW

The current work examined the potential of using ARV-825 and ABBV-744 to enhance the effectiveness of tamoxifen or fulvestrant furthermore palbociclib. ARV-825 was effective in both equally p53 wild-type (WT) breast tumor cells As well as in cells missing purposeful p53 possibly by itself or in combination with tamoxifen, whilst the effectiveness o